MAP2K7 and melanoma: Combinations of SRC and MEK inhibitors have shown benefit in preclinical studies across several tumour types including ovarian, melanoma, non‐small‐cell lung carcinoma, breast and other solid tumours [56, 57, 58, 59, 60, 61, 62, 63].